Related references
Note: Only part of the references are listed.Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure
Henrike Arfsten et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction A Report of the American College of Cardiology Solution Set Oversight Committee
Thomas M. Maddox et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening
Elnaz Poorgolizadeh et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Abstracts
[Anonymous]
KIDNEY INTERNATIONAL (2021)
Renal protection in chronic heart failure: focus on sacubitril/valsartan
Roberto Pontremoli et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
Scott D. Solomon et al.
CIRCULATION (2020)
Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF
Muthiah Vaduganathan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan
Senthil Selvaraj et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Election Fraction
Jonathan W. Cunningham et al.
JACC-HEART FAILURE (2020)
Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials
Qiang Geng et al.
CARDIOLOGY (2020)
Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction
Finnian R. Mc Causland et al.
CIRCULATION (2020)
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction:PARAGON-HF
Senthil Selvaraj et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists
Andrew P. Ambrosy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Circulating products of C-type natriuretic peptide and links with organ function in health and disease
Timothy C. R. Prickett et al.
PEPTIDES (2020)
BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era
Marco Sbolli et al.
CURRENT CARDIOLOGY REPORTS (2020)
Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control
Jelena P. Seferovic et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2020)
Atrial and brain natriuretic peptides: Hormones secreted from the heart
Yasuaki Nakagawa et al.
PEPTIDES (2019)
Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia A Randomized Clinical Trial
Jeff D. Williamson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology
Petar M. Seferovic et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
C-Type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature
Amie J. Moyes et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial
David A. Morrow et al.
CIRCULATION (2019)
Effect and safety of LCZ696 in the treatment of hypertension A meta-analysis of 9 RCT studies
Qiongqiong Li et al.
MEDICINE (2019)
Outcomes and Effect of Treatment According to Etiology in HFrEF An Analysis of PARADIGM-HF
Craig Balmforth et al.
JACC-HEART FAILURE (2019)
Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
Akshay S. Desai et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
S. D. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ivabradine for the Treatment of Cardiovascular Diseases
Tomomi Ide et al.
CIRCULATION JOURNAL (2019)
Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study
Helene Nougue et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure
Eric J. Velazquez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Anti-Hypertensive Effect of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials
Renato De Vecchis et al.
CARDIOLOGY RESEARCH (2019)
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF
Ulrik M. Mogensen et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension
Stefan Engeli et al.
HYPERTENSION (2018)
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure)
Orly Vardeny et al.
CIRCULATION-HEART FAILURE (2018)
Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure
Milton Packer
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
Ulrik M. Mogensen et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Neprilysin inhibition and endothelin-1 elevation: Focus on the kidney
Lodi C. W. Roksnoer et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study
Deanna G. Cheung et al.
JOURNAL OF CLINICAL HYPERTENSION (2018)
The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients
R. Stinkens et al.
SCIENTIFIC REPORTS (2018)
The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond
Kazuomi Kario
CURRENT CARDIOLOGY REPORTS (2018)
Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
Kevin Damman et al.
JACC-HEART FAILURE (2018)
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure A Secondary Analysis of the PARADIGM-HF Trial
Alvin Chandra et al.
JAMA CARDIOLOGY (2018)
Neprilysin Inhibitors and Bradykinin
Duncan J. Campbell
FRONTIERS IN MEDICINE (2018)
Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension
J. Jordan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction
Jane A. Cannon et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension
Tzung-Dau Wang et al.
HYPERTENSION (2017)
Long-term neprilysin inhibition - implications for ARNIs
Duncan J. Campbell
NATURE REVIEWS CARDIOLOGY (2017)
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study
Roland E. Schmieder et al.
EUROPEAN HEART JOURNAL (2017)
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF
Michael Bohm et al.
EUROPEAN HEART JOURNAL (2017)
Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides
Emilia D'Elia et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension The PARAMETER Study
Bryan Williams et al.
HYPERTENSION (2017)
Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study
Joseph L. Izzo et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2017)
The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey
Heidi A. Schoenfeld et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2017)
Sacubitril/valsartan in PARADIGM-HF (Publication with Expression of Concern. See vol. 7, pg. 250, 2019) (Publication with Expression of Concern. See vol. 7, pg. 250, 2019)
Nicolas Vodovar et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
Jelena P. Seferovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥ 65 Years) With Systolic Hypertension
Ouppatham Supasyndh et al.
AMERICAN JOURNAL OF HYPERTENSION (2017)
Sacubitril/valsartan in PARADIGM-HF
Dayana Flores et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Cardiac Natriuretic Peptides, Hypertension and Cardiovascular Risk
Riccardo Sarzani et al.
HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION (2017)
LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension
Kazuomi Kario et al.
JOURNAL OF CLINICAL HYPERTENSION (2016)
Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials
Xinfang Xie et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Natriuretic peptide control of energy balance and glucose homeostasis
Marine Coue et al.
BIOCHIMIE (2016)
The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects
Thomas H. Langenickel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)
Naoki Okumura et al.
CIRCULATION (2016)
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial
Scott D. Solomon et al.
CIRCULATION-HEART FAILURE (2016)
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy
Naoki Okumura et al.
CIRCULATION-HEART FAILURE (2016)
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial
Soren L. Kristensen et al.
CIRCULATION-HEART FAILURE (2016)
Geographic variations in the PARADIGM-HF heart failure trial
Soren Lund Kristensen et al.
EUROPEAN HEART JOURNAL (2016)
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial
Orly Vardeny et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan
Pardeep S. Jhund et al.
HEART (2016)
Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization
Akshay S. Desai et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure
Michael R. Zile et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation The PARADIGM-HF Trial
Scott D. Solomon et al.
JACC-HEART FAILURE (2016)
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
Akshay S. Desai et al.
EUROPEAN HEART JOURNAL (2015)
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
Pardeep S. Jhund et al.
EUROPEAN HEART JOURNAL (2015)
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction
Adriaan A. Voors et al.
EUROPEAN JOURNAL OF HEART FAILURE (2015)
Heart failure as a general pandemic in Asia
Hiroaki Shimokawa et al.
EUROPEAN JOURNAL OF HEART FAILURE (2015)
Molecular-Based Mechanisms of Mendelian Forms of Salt-Dependent Hypertension Questioning the Prevailing Theory
Theodore W. Kurtz et al.
HYPERTENSION (2015)
Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction
Sadayoshi Ito et al.
HYPERTENSION RESEARCH (2015)
Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores
Joanne Simpson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
ANP-induced signaling cascade and its implications in renal pathophysiology
Franziska Theilig et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Milton Packer et al.
CIRCULATION (2015)
Natriuretic peptides in cardiovascular diseases: current use and perspectives
Massimo Volpe et al.
EUROPEAN HEART JOURNAL (2014)
Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension
Kazuomi Kario et al.
HYPERTENSION (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Natriuretic hormones in brain function
Anastasia Hodes et al.
FRONTIERS IN ENDOCRINOLOGY (2014)
Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies
Speranza Rubattu et al.
JOURNAL OF HYPERTENSION (2013)
Nocturnal blood pressure and cardiovascular disease: a review of recent advances
Yuichiro Yano et al.
HYPERTENSION RESEARCH (2012)
Mechanisms and Treatment of CKD
Piero Ruggenenti et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
Scott D. Solomon et al.
LANCET (2012)
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
Luis Miguel Ruilope et al.
LANCET (2010)
Atrial Natriuretic Peptide Induces Postprandial Lipid Oxidation in Humans
Andreas L. Birkenfeld et al.
DIABETES (2008)
Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial
Ruth Peters et al.
LANCET NEUROLOGY (2008)
Central pressure more strongly relates to vascular disease and outcome than does brachial pressure - The strong heart study
Mary J. Roman et al.
HYPERTENSION (2007)
The role of natriuretic peptides in cardioprotection
T Nishikimi et al.
CARDIOVASCULAR RESEARCH (2006)
Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults
K Sutton-Tyrrell et al.
CIRCULATION (2005)
Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans
AL Birkenfeld et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients
ML Muiesan et al.
HYPERTENSION (2004)
Renal insufficiency and heart failure - Prognostic and therapeutic implications from a prospective cohort study
FA McAlister et al.
CIRCULATION (2004)
Omapatrilat and enalapril in patients with hypertension: The omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial
OB Kostis et al.
AMERICAN JOURNAL OF HYPERTENSION (2004)
Arterial stiffness and the systolic hypertension syndrome
JL Izzo
CURRENT OPINION IN CARDIOLOGY (2004)
Comparison of omapatrilat chronic and enalapril in patients with heart failure - The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)
M Packer et al.
CIRCULATION (2002)
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
JL Rouleau et al.
LANCET (2000)
Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
MW Taal et al.
KIDNEY INTERNATIONAL (2000)
Share Paper
